Trial Profile
A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated with Distributive Shock
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Angiotensin II (Primary)
- Indications Hypotension
- Focus Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 05 Oct 2021 This trial has been suspended in Spain, according to European Clinical Trials Database record.
- 19 Jul 2019 This trial has been completed in Estonia , according to European Clinical Trials Database.
- 30 May 2019 This trial has been discontinued in Lithuania, according to European Clinical Trials Database.